SYF737e4ac03e1a4aaa9f95b569b7388822Registry ID: 2024-510629-24-00|RecruitingPhase 2
Management of Parkinson's disease if levodopa is broken down prematurely
Management of peripheral levodopa resistance in Parkinson’s disease
Loading search results
Management of peripheral levodopa resistance in Parkinson’s disease
interventional
N/A
1 country
1
Can symptom management of persons with Parkinson's disease who have increased activity of the levodopa-metabolizing enzyme aromatic L-amino acid decarboxylase (AADC), or who have increased abundance of bacteria that produce the levodopa-metabolizing enzymes tyrosine decarboxylase (TDC), aromatic amino acid aminotransferase (AAT) or aromatic amino acid lactate dehydrogenase (ALDH), be improved by either circumventing the enzymatic mechanisms (using the dopamine receptor agonist apomorphine), or an antibiotic intervention against enzyme-producing bacteria (rifaximin), or both?
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 30, 2024
Actual (reported)Proportion of responders (defined as >30.0% decrease in MDS-UPDRS-III compared to pre-treatment), apomorphine versus levodopa
MDS-UPDRS-IIIΔOFF-ONΔposttreatment-pretreatment, rifaximin compared to placebo
MDS-UPDRS IIIΔOFF-ON
Composite Clinical Motor Score (CCMS)
Modified Hoehn & Yahr scale
Global Rating of Change (GRC)
Modified GIDS-PD
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Domperidon Accord 10 mg, tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
XIFAXAN 550 mg filmomhulde tabletten
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Domperidon Accord 10 mg, tabletten
Named ingredient: Domperidone
View registry recordXIFAXAN 550 mg filmomhulde tabletten
Named ingredient: Rifaximin
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Radboud universitair medisch centrum Stichting
Nijmegen, 6525 GA, Netherlands
Research Support Helpdesk
First Submitted
August 30, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.